Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 18/20 | 1.00 |
| ▸ | PLA2G4C | Q9UP65 | 2/20 | 0.92 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.58 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22222825 | 0.77 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6HCRTR1HCRTR2 | |
| SCHEMBL22222878 | 0.77 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6 | |
| SCHEMBL29367824 | 0.73 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6 | |
| SCHEMBL22222834 | 0.73 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6 | |
| SCHEMBL3686137 | 0.73 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6 | |
| SCHEMBL2729842 | 0.73 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6 | |
| SCHEMBL22187659 | 0.73 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6 | |
| SCHEMBL22222880 | 0.73 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6 | |
| SCHEMBL22222879 | 0.73 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6 | |
| SCHEMBL22222829 | 0.69 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370411-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | OPHIREX INC (US) | 2022-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370411-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | PLA2G12A, PLA2G3, PLA2G1B | PLA2G4A 11/4885PLA2G4C 25/4885PLA2G6 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.